Open AccessThis article is
- freely available
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
Genetic Medicine, St Mary\'s Hospital, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Oxford Road, Manchester, M13 9WL, UK
* Author to whom correspondence should be addressed.
Received: 30 December 2009; in revised form: 12 March 2010 / Accepted: 9 April 2010 / Published: 15 April 2010
Abstract: Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy.
Keywords: tamoxifen; CYP2D6 genotyping; breast cancer
Citations to this Article
Cite This Article
MDPI and ACS Style
Ferraldeschi, R.; Newman, W.G. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals 2010, 3, 1122-1138.
Ferraldeschi R, Newman WG. The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals. 2010; 3(4):1122-1138.
Ferraldeschi, Roberta; Newman, William G. 2010. "The Impact of CYP2D6 Genotyping on Tamoxifen Treatment." Pharmaceuticals 3, no. 4: 1122-1138.